WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 556014
Description: ALC-0159 is a PEG/lipid conjugate (i.e. PEGylated lipid), specifically, it is the N,N-dimyristylamide of 2-hydroxyacetic acid, O-pegylated to a PEG chain mass of about 2 kilodaltons (corresponding to about 45-46 ethylene oxide units per molecule of N,N-dimyristyl hydroxyacetamide). It is a non-ionic surfactant by its nature. It has been deployed in the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine that contains the active ingredient tozinameran.
MedKoo Cat#: 556014
Chemical Formula: (C2H4O)nC31H63NO2
Molecular Weight: 2450.0
Synonym: ALC-0159; ALC 0159; ALC0159;
IUPAC/Chemical Name: 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
InChi Key: BPWFJNQUTKVHIR-UHFFFAOYSA-N
InChi Code: InChI=1S/C33H67NO3/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-34(33(35)32-37-31-30-36-3)29-27-25-23-21-19-17-15-13-11-9-7-5-2/h4-32H2,1-3H3
SMILES Code: CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)C(COCCOC)=O
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
|Biological target:||ALC-0159 is a polyethylene glycol (PEG) lipid conjugate that could be used as vaccine excipient.|
|In vitro activity:||ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. The LNPs in the Pfizer-BioNTech COVID-19 vaccine contain low levels (<2 mol %) of ALC-0159, which contributes to nanoparticle stabilization by a steric mechanism through its poly(ethylene glycol) (PEG) moiety. Considering their low ALC-0159 content, LNPs in the Pfizer-BioNTech COVID-19 vaccine most likely display a weak steric barrier of PEG. Reference: Mol Ther. 2021 Mar 3;29(3):898-900. https://pubmed.ncbi.nlm.nih.gov/33571463/|
|In vivo activity:||TBD|
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 2450.0 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
|Formulation protocol:||1. Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021 Mar 3;29(3):898-900. doi: 10.1016/j.ymthe.2021.01.030. Epub 2021 Feb 5. PMID: 33571463; PMCID: PMC7862013.|
|In vitro protocol:||1. Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021 Mar 3;29(3):898-900. doi: 10.1016/j.ymthe.2021.01.030. Epub 2021 Feb 5. PMID: 33571463; PMCID: PMC7862013.|
|In vivo protocol:||TBD|